Cream Veterinary Grade API is supplied as a white to off-white crystalline powder for downstream pharmaceutical manufacturing. The commercial designation “Cream” identifies the product platform and not a semisolid topical cream. The platform includes four release-controlled models: CVG-API-TB for direct compression tablets and capsules, CVG-API-INJ for injectable solutions and suspensions, CVG-API-PM for medicated premixes and granular feed intermediates, and CVG-API-SOL for oral solutions and reconstituted powders. The material is manufactured under active pharmaceutical ingredient GMP in accordance with ICH Q7 and relevant national veterinary medicinal product regulations. It is assigned compendial-grade acceptance criteria as a starting material; it is not a formulated premix, and it is not released as sterile.

The primary operational difference from many veterinary-grade raw materials is the application of a single control file across all four models. Instead of qualifying separate oral, injectable, and premix grades from different suppliers, a dosage-form manufacturer can qualify one API line and then select the model-specific milling, endotoxin, moisture, and packaging configuration required by the formulation. The following sections describe the release attributes and processing boundaries for each model. Where process values are quoted, they are representative production-scale ranges and must be verified against site equipment, formulation, and current compendial monographs.

What Physicochemical Controls Are Applied to the Direct Compression and Capsule Model?

For the tablet and capsule models, release begins with particle size distribution by laser diffraction according to Ph. Eur. 2.9.31 and USP <429>. The CVG-API-TB model is controlled to a D50 between 90 µm and 150 µm and a D90 not more than 250 µm. The upper D90 limit reduces the risk of weight variation during high-speed tablet compression; the lower D50 limit avoids the cohesive flow behaviour that can lead to die filling variability and sticking. Bulk density is maintained between 0.45 g/mL and 0.65 g/mL, tapped density between 0.55 g/mL and 0.80 g/mL, and the Hausner ratio between 1.20 and 1.35, using Ph. Eur. 2.9.34 and USP <616>. Polymorphic identity is confirmed by X-ray powder diffraction using USP <941>, and loss on drying is controlled to not more than 0.5% by Ph. Eur. 2.2.32 and USP <731>.

In an instrumented rotary tablet press, representative direct compression values are main compression force 8–18 kN, precompression force 3–6 kN, and turret speed 25–60 rpm. When the API is blended at 20% by weight in microcrystalline cellulose and dibasic calcium phosphate, compact tensile strength should generally be evaluated in the range of 1.0–1.8 MPa to resist capping; published data for this specific formulation configuration is limited, and tablets must be developed using the intended excipient matrix. Ejection force should be maintained below 700 N to avoid excessive tooling wear. The model is not optimised for roll compaction or slugging; high-shear granulation may be used, but the particle size will change and the direct compression advantage may be lost.

Hard capsule filling on a tamping pin machine at 2,000–5,000 capsules/min requires the same flow limits. If the D90 exceeds 250 µm, pin compaction can generate variable slug densities, and if the D50 falls below 60 µm, powder may escape between the lower pin and die bore. The CVG-API-TB model therefore avoids a single fine-particle target in favour of a controlled full-size distribution.

Injections require tighter bioburden and endotoxin control than oral models. The CVG-API-INJ model is released with bacterial endotoxin not exceeding 0.05 EU/mg by Ph. Eur. 2.6.14 and USP <85>, total aerobic microbial count below 100 CFU/g, and total yeast and mold count below 10 CFU/g by Ph. Eur. 2.6.12/2.6.13 and USP <61>/<62>. The material is not terminally sterilized and is not supplied as sterile powder; downstream aseptic filtration or moist-heat terminal sterilisation must be validated by the drug product manufacturer. For injectable suspension formulations, the particle size target is D50 5–15 µm and D90 not more than 25 µm by Ph. Eur. 2.9.31. Residual solvent control follows ICH Q3C and VICH GL18; class 1 solvents are absent at a reporting threshold of 1 ppm, and class 2 solvents are controlled below permitted daily exposure. Elemental impurity limits follow ICH Q3D, USP <232>/<233>, and Ph. Eur. 2.4.20 for parenteral administration. As with many weakly acidic APIs, the injection model should not be combined with calcium-containing diluents without a compatibility screen, because precipitation can occur above 10 mg/mL in certain aqueous media.

When a Medicated Premix Requires Uniform Distribution in Final Feed

Uniformity in medicated premix applications is controlled by assay and blend uniformity after mixing in production-scale ribbon or paddle mixers. For CVG-API-PM, recovery by high-performance liquid chromatography using Ph. Eur. 2.2.29 or USP <621> should be between 90% and 110% of label claim, with relative standard deviation not more than 5.0%. The model is milled to a D50 of 150–300 µm and D90 not more than 600 µm to reduce electrostatic adhesion and improve flow through volumetric screw conveyors. Bulk density is held between 0.50 g/mL and 0.70 g/mL to stabilise dosing under high-humidity feed mill conditions. The grade is not intended for direct feeding to animals; it is a controlled intermediate for licensed medicated premix production and must be diluted with a compatible feed carrier.

Segregation studies with a 500 kg batch in a double-ribbon mixer show that blending for 10 min at 20 rpm is generally sufficient, but discharge into bulk bags can create fine-particle enrichment if the powder is allowed to free-fall more than 2 m. Where possible, the premix should be transferred by low-velocity pneumatic conveyor or gravity chute with baffles to avoid air classification. If the relative humidity in the production hall exceeds 60%, the material should be discharged promptly and the hopper sealed, because moisture uptake can raise flow variability.

Wet-granulation and powder-fill processes use the same crystalline form as the direct compression model but require particle size adjustment or pre-compaction. In high-shear granulation, the API is charged with binder solution at a spray rate of 0.2–0.5 L/min per 100 kg dry blend and granulated to an impeller power consumption endpoint rather than a fixed time. Drying in a fluid-bed dryer is limited to inlet air temperature 60–70°C and product temperature not exceeding 45°C to avoid amorphous content above 2.0% by X-ray powder diffraction. Material dried above this threshold can show reduced flow and increased sticking on tablet tooling. When the API is dry-filled into capsule dosators, lubrication with magnesium stearate at 0.25–0.5% is common, but blending beyond 3 min at high shear can reduce dissolution due to hydrophobic film formation. The granulation path is preferred when the formulation requires drug load above 40% or when the direct compression blend has poor flow. Milled granulate should be passed through a 0.8 mm screen after dry milling; fines below 75 µm should not exceed 20% of the granulate mass to prevent segregation during capsule filling.

Residual Solvent and Elemental Impurity Control in Multi-Species Markets

The full platform is released against ICH Q3C, VICH GL18, and USP <467> residual solvent criteria. Class 1 solvents are controlled as not detected with a reporting threshold of 1 ppm; class 2 solvents are measured by headspace gas chromatography and limited to the permitted daily exposure concentration for the intended species and duration. Elemental impurities are controlled according to ICH Q3D, USP <232>/<233>, and Ph. Eur. 2.4.20, with limits selected for oral and parenteral routes as applicable. The analytical package includes arsenic, cadmium, lead, mercury, cobalt, nickel, and vanadium where the route of administration or species-specific toxicology requires it. These controls distinguish the product from technical-grade feed additives that are not released under API GMP and may not provide a full elemental impurity profile.

The oral solution model, CVG-API-SOL, is milled to a D50 of 100–200 µm and is packaged in double low-density polyethylene bags inside a sealed aluminium laminate pouch with a desiccant. pH-dependent solubility is evaluated at 25°C and 40°C in buffer solutions from pH 3.0 to 7.0, with sampling under ICH Q1A or VICH GL3 conditions. If no antimicrobial preservative is present, solutions should be used within 24 hours, because unpreserved oral vehicles can exceed the acceptance criterion of 100 CFU/mL. For drinking water administration, a concentrated stock solution is preferred over direct dry addition, because undissolved particles can settle at concentrations above 1 g/L in hard water with high calcium content.

The Multi-Dosage-Form Platform Uses a Single Master Batch Record Across Four Model Grades

Most veterinary APIs are released as separate oral, injectable, or premix grades with independent particle size targets, residual solvent justifications, and stability files. Cream Veterinary Grade API uses a single master batch record for the crystallised API and applies model-specific milling, endotoxin control, and packaging after final quality attribute testing. This reduces the number of vendor qualifications from up to four to one while preserving route-specific limits. Injectable model specifications are not automatically applied to oral models, but the analytical methods and impurity reference standards are shared. The platform is not suitable for compounded topical creams or for direct sale to unlicensed feed mills in jurisdictions where GMP-grade APIs are restricted to licensed product manufacture. Published data for stability beyond 36 months is limited; sites should establish retest intervals under their own climate zone conditions using ICH Q1A or VICH GL3 as applicable.